Trial 9L-21-7


A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome (SELECT-MDS-1)

Type: Treatment
Phase: Phase III
Status: Open to Accrual
Treatments: Biological Response Modifier
Randomized: Yes
USC Satellite Location: None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Casey O'Connell, M.D.
Other Trial Staff:  Simbiso Peresuh, Coordinator, Suraj Chandwani, D.M., Ashot Minasyan, D.M., Christine Duran, Coordinator, Donna Fernando, Coordinator, Nelli Dimitrova, D.M., Hannah Trey, Coordinator, Sonny Tong, D.M., Adrianne Harding, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.